Nursing Elites

1. A client has a prescription for ceftriaxone. Which of the following information should the nurse include in the teaching?

• A. You may develop a cough while taking this medication.
• B. You should stop taking this medication if you develop a rash.
• C. This medication cannot be given orally.
• D. This medication may cause your urine to turn yellow.

Correct answer: B

Rationale: The correct answer is B. A rash can indicate an allergic reaction to ceftriaxone, which should be reported to the provider. It is crucial to instruct the client to discontinue the medication and seek medical attention if a rash develops to prevent potential serious adverse effects. Choices A, C, and D are incorrect because cough is not a common side effect of ceftriaxone, ceftriaxone is typically administered parenterally, and a yellow discoloration of urine is a harmless side effect due to the color of the medication itself, respectively.

2. A client is receiving Enoxaparin for the prevention of deep vein thrombosis. Which of the following actions should the nurse take?

• A. Massage the injection site after administration.
• B. Administer the medication intramuscularly.
• C. Administer the medication into the subcutaneous tissue.
• D. Administer the medication into the deltoid muscle.

Correct answer: C

Rationale: Enoxaparin, a medication used for preventing deep vein thrombosis, should be administered into the subcutaneous tissue, typically in the abdomen. Administering the medication intramuscularly (Choice B) or into the deltoid muscle (Choice D) is incorrect because Enoxaparin is specifically formulated for subcutaneous administration. Massaging the injection site after administration (Choice A) is contraindicated as it may lead to tissue damage and affect the absorption of the medication. Therefore, the correct action is to administer the medication into the subcutaneous tissue as directed.

3. A nurse is providing instructions to a client who has a prescription for Amoxicillin and Clarithromycin to treat a Peptic Ulcer. Which of the following information should the nurse include in the teaching?

• A. Take these medications with foo '
• B. These medications can turn your stool black.'
• C. These medications can cause photosensitivity.'
• D. The purpose of these medications is to decrease the pH of gastric juices in the stomach.'

Correct answer: A

Rationale: The nurse should instruct the client to take these medications with food to reduce GI disturbances.

4. A client has a new prescription for Fluoxetine for PTS. Which of the following statements should the nurse include in the teaching?

• A. You may have a decreased desire for intimacy while taking this medication.
• B. You should take this medication at bedtime to help promote sleep.
• C. You will have fewer urinary adverse effects if you urinate just before taking this medication.
• D. You'll need to wear sunglasses when outdoors due to the light sensitivity caused by this medication.

Correct answer: A

Rationale: The correct statement for the nurse to include in the teaching is 'You may have a decreased desire for intimacy while taking this medication.' One of the potential adverse effects of fluoxetine and other SSRIs is a decreased desire for intimacy. It is essential for the nurse to educate the client about this possible side effect to enhance understanding and promote informed decision-making. Choices B, C, and D are incorrect because they do not relate to common side effects of Fluoxetine that the nurse should include in the teaching.

5. A client with Hodgkin's disease is receiving Cyclophosphamide IV. Which medication should be administered concurrently to prevent an adverse effect of Cyclophosphamide?

• A. Uroprotectant agent, such as mesna
• B. Opioid, such as morphine
• C. Loop diuretic, such as furosemide
• D. H1 receptor antagonist, such as diphenhydramine

Correct answer: A

Rationale: Mesna, an uroprotectant agent, is administered with nitrogen mustard chemotherapy drugs like Cyclophosphamide to prevent hemorrhagic cystitis, a common adverse effect. Mesna works by binding to and inactivating the toxic metabolites of Cyclophosphamide in the bladder, thereby reducing the risk of bladder toxicity.

Similar Questions